卵巢癌患者血清中ROBO4、sB7-H4含量与肿瘤病理特征的相关性研究
|
摘要
目的:研究卵巢癌患者血清中ROBO4、可溶性B7-H4(sB7-H4)含量与肿瘤病理特征的相关性。方法:选择本院手术切除治疗的卵巢癌患者及卵巢良性肿瘤患者,测定血清中ROBO4、sB7-H4的含量以及病灶组织中ROBO4、B7-H4、癌基因的表达量。结果:卵巢癌患者血清中ROBO4的含量较卵巢良性肿瘤患者显著降低,sB7-H4的含量较卵巢良性肿瘤患者显著升高;卵巢癌组织中ROBO4的mRNA表达量较卵巢良性肿瘤组织显著降低,B7-H4的mRNA表达量较卵巢良性肿瘤组织显著升高,且卵巢癌患者血清中ROBO4、sB7-H4的含量与卵巢癌组织中ROBO4、B7-H4的mRNA表达量具有正相关关系;肿瘤的FIGO分期及病理分级越高,卵巢癌患者血清中ROBO4的含量越低、sB7-H4的含量越高;卵巢癌组织中β-catenin、CyclinD1、MMP9的mRNA表达量与卵巢良性肿瘤组织比较显著升高且与ROBO4呈负相关、与sB7-H4呈正相关,PTEN、E-cadherin的mRNA表达量与卵巢良性肿瘤组织比较显著降低且与ROBO4呈正相关、与sB7-H4呈负相关。结论:卵巢癌患者血清中ROBO4、sB7-H4含量的变化与肿瘤临床病理分期改变、癌基因异常表达均密切相关。
Objective: To study the correlation of serum ROBO4 and soluble B7-H4(sB7-H4) contents with the pathological features of tumor in patients with ovarian cancer. Methods: The patients with ovarian cancer and the patients with ovarian benign tumor who underwent surgical resection in our hospital between March 2015 and August 2017 were selected, and the contents of ROBO4 and sB7-H4 in serum as well as the expression of ROBO4, B7-H4 and oncogenes in the lesion tissues were determined. Results: ROBO4 content in serum of patients with ovarian cancer was significantly lower than that of patients with ovarian benign tumor whereas sB7-H4 content was significantly higher than that of patients with ovarian benign tumor, ROBO4 mRNA expression in ovarian cancer tissues was significantly lower than that in ovarian benign tumor tissues whereas B7-H4 mRNA expression was significantly higher than that in ovarian benign tumor tissues, and ROBO4 and sB7-H4 contents in serum of patients with ovarian cancer were positively correlated with ROBO4 and B7-H4 mRNA expression in ovarian cancer tissues; the higher the FIGO stage and pathological grade of the tumor, the lower the ROBO4 content and the higher the sB7-H4 content in serum of patients with ovarian cancer; β-catenin, CyclinD1 and MMP9 mRNA expression in ovarian cancer tissues were significantly higher than those in ovarian benign tumor tissues, negatively correlated with ROBO4 and positively correlated with sB7-H4 whereas PTEN and E-cadherin mRNA expression were significantly lower than those in ovarian benign tumor tissues, positively correlated with ROBO4 and negatively correlated with sB7-H4. Conclusion: The changes of ROBO4 and sB7-H4 contents in serum of patients with ovarian cancer are closely related to the changes of clinicopathologic stage and the abnormal expression of oncogenes.
Objective: To study the correlation of serum ROBO4 and soluble B7-H4(sB7-H4) contents with the pathological features of tumor in patients with ovarian cancer. Methods: The patients with ovarian cancer and the patients with ovarian benign tumor who underwent surgical resection in our hospital between March 2015 and August 2017 were selected, and the contents of ROBO4 and sB7-H4 in serum as well as the expression of ROBO4, B7-H4 and oncogenes in the lesion tissues were determined. Results: ROBO4 content in serum of patients with ovarian cancer was significantly lower than that of patients with ovarian benign tumor whereas sB7-H4 content was significantly higher than that of patients with ovarian benign tumor, ROBO4 mRNA expression in ovarian cancer tissues was significantly lower than that in ovarian benign tumor tissues whereas B7-H4 mRNA expression was significantly higher than that in ovarian benign tumor tissues, and ROBO4 and sB7-H4 contents in serum of patients with ovarian cancer were positively correlated with ROBO4 and B7-H4 mRNA expression in ovarian cancer tissues; the higher the FIGO stage and pathological grade of the tumor, the lower the ROBO4 content and the higher the sB7-H4 content in serum of patients with ovarian cancer; β-catenin, CyclinD1 and MMP9 mRNA expression in ovarian cancer tissues were significantly higher than those in ovarian benign tumor tissues, negatively correlated with ROBO4 and positively correlated with sB7-H4 whereas PTEN and E-cadherin mRNA expression were significantly lower than those in ovarian benign tumor tissues, positively correlated with ROBO4 and negatively correlated with sB7-H4. Conclusion: The changes of ROBO4 and sB7-H4 contents in serum of patients with ovarian cancer are closely related to the changes of clinicopathologic stage and the abnormal expression of oncogenes.
引文
1 Antonijevic A,Rancic N,Ilic M,et al.Incidence and mortality trends of ovarian cancer in central Serbia [J].J BUON,2017,22(2):508-512.
2 谭细凤,李怀芳,谷雨枫.新辅助化疗联合肿瘤细胞减灭术治疗晚期上皮性卵巢癌的随访观察[J].实用妇产科杂志,2017,33(1):62-65.
3 Bekes I,Haunerdinger V,Sauter R,et al.Slit2/Robo4 signaling:Potential role of a VEGF-Antagonist pathway to regulate luteal permeability[J].Geburtshilfe Frauenheilkd,2017,77(1):73-80.
4 Liang L,Jiang Y,Chen JS,et al.B7-H4 expression in ovarian serous carcinoma:a study of 306 cases [J]Hum Pathol,2016,57:1-6.
5 马瑞琼,叶雪,程洪艳,等.ROBO4 在上皮性卵巢癌组织和血清中的表达及临床意义[J].解剖学报,2014,45(1):64-69.
6 李春仙,陈洁,彭岚.sB7-H4 蛋白和 CA125 联检在卵巢癌患者中的应用价值[J].放射免疫学杂志,2013,26(5):635-636.
7 Xu M,Zhang B,Zhang M,et al.Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer[J].Oncol Lett,2016,11(4):2815-2819.
8 Qin N,Fan XC,Zhang YY,et al.New insights into implication of the SLIT/ROBO pathway in the prehierarchical follicle development of hen ovary[J].Poult Sci,2015,94(9):2235-2246.
9 Tao Y,Li H,Huang R,et al.Clinicopathological and prognostic significance of cancer stem cell markers in ovarian cancerpatients:evidence from 52 studies[J].Cell Physiol Biochem,2018,46(4):1716-1726.
10 Hatano Y,Fukuda S,Makino H,et al.High-grade serous carcinoma with discordant p53 signature:report of a case with new insight regarding high-grade serous carcinogenesis [J].Diagn Pathol,2018,13(1):24.
11 Rasool M,Malik A,Basit Ashraf MA,et al.Evaluation of matrix metalloproteinases,cytokines and their potential role in the development of ovarian cancer [J].PLoS One,2016,11(11):e0167149.
12 Russo A,Czarnecki AA,Dean M,et al.PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation[J].Oncogene,2018,37(15):1976-1990.
13 Oral D,Erkekoglu P,Kocer-Gumusel B,et al.Epithelial-mesenchymal transition:A special focus on phthalates and bisphenol a[J].J Environ Pathol Toxicol Oncol,2016,35(1):43-58.
2 谭细凤,李怀芳,谷雨枫.新辅助化疗联合肿瘤细胞减灭术治疗晚期上皮性卵巢癌的随访观察[J].实用妇产科杂志,2017,33(1):62-65.
3 Bekes I,Haunerdinger V,Sauter R,et al.Slit2/Robo4 signaling:Potential role of a VEGF-Antagonist pathway to regulate luteal permeability[J].Geburtshilfe Frauenheilkd,2017,77(1):73-80.
4 Liang L,Jiang Y,Chen JS,et al.B7-H4 expression in ovarian serous carcinoma:a study of 306 cases [J]Hum Pathol,2016,57:1-6.
5 马瑞琼,叶雪,程洪艳,等.ROBO4 在上皮性卵巢癌组织和血清中的表达及临床意义[J].解剖学报,2014,45(1):64-69.
6 李春仙,陈洁,彭岚.sB7-H4 蛋白和 CA125 联检在卵巢癌患者中的应用价值[J].放射免疫学杂志,2013,26(5):635-636.
7 Xu M,Zhang B,Zhang M,et al.Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer[J].Oncol Lett,2016,11(4):2815-2819.
8 Qin N,Fan XC,Zhang YY,et al.New insights into implication of the SLIT/ROBO pathway in the prehierarchical follicle development of hen ovary[J].Poult Sci,2015,94(9):2235-2246.
9 Tao Y,Li H,Huang R,et al.Clinicopathological and prognostic significance of cancer stem cell markers in ovarian cancerpatients:evidence from 52 studies[J].Cell Physiol Biochem,2018,46(4):1716-1726.
10 Hatano Y,Fukuda S,Makino H,et al.High-grade serous carcinoma with discordant p53 signature:report of a case with new insight regarding high-grade serous carcinogenesis [J].Diagn Pathol,2018,13(1):24.
11 Rasool M,Malik A,Basit Ashraf MA,et al.Evaluation of matrix metalloproteinases,cytokines and their potential role in the development of ovarian cancer [J].PLoS One,2016,11(11):e0167149.
12 Russo A,Czarnecki AA,Dean M,et al.PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation[J].Oncogene,2018,37(15):1976-1990.
13 Oral D,Erkekoglu P,Kocer-Gumusel B,et al.Epithelial-mesenchymal transition:A special focus on phthalates and bisphenol a[J].J Environ Pathol Toxicol Oncol,2016,35(1):43-58.